NeoStem is building a dominant IP portfolio within the field of cell therapy to protect its cutting edge technologies. Notably, this patent estate includes composition of matter patents for Athelos (2023) and AMR-001 (2028). The patent estate includes over 30 issued patents, over 90 pending patent applications, composition of matter and method claims, and a geographic breadth of filings including North America, Europe, Asia, Australia, Israel and South Africa. NeoStem IP focuses on immunology, cardiology, orthopedic, wound healing, age related tissue restoration, stem cell isolation, collection, and storage, and VSEL discovery and applications.

NEOSTEM'S PATENT APPLICATIONS (not through subsidiaries)

• NeoStem has developed certain technologies regarding the apheresed collection, isolation, and storage of adult autologous stem cells.
• In-licensed from the University of Louisville the world-wide patent rights and know-how regarding very small embryonic-like (VSEL) stem cells, their isolation, purification and therapeutic use.
• Joint inventorship with the University of Michigan for a provisional patent using VSELs for the repair and regeneration of bone tissue.
• In-licensed rights to therapeutic stem cell treatments for wound healing, cartilage repair and restoration of age-related tissue loss in the face.

ATHELOS PATENTS AND PENDING PATENTS

• In-licensed from the University of Pennsylvania, the University of Minnesota and the University of Southern California the exclusive world-wide rights to a broad patent estate comprised of approximately 30 issued patents and approximately 50 pending patent applications
• Athelos holds composition of matter patents and method patents, mostly relating to the isolation and expansion of Regulatory T cells

AMORCYTE PATENTS AND PENDING PATENTS

•  Amorcyte was granted U.S. patent number 7,794,705 titled "Compositions and Methods of Vascular Injury Repair." 
• The patent contains both composition of matter and method claims surrounding a therapeutic chemotactic hematopoietic stem cell product used in treating or repairing vascular injury following an acute myocardial infarction. 
• The patented pharmaceutical composition is comprised of autologous non-expanded CD34+ cells with an enriched subpopulation of CXCR4+ cells. 
• Pending patent application filings are entitled “Infarct Area Perfusion-Improving Compositions and Methods of vascular Injury Repair,” and “Compositions and Methods for Treating Progressive Myocardial Injury Due to a Vascular Insufficiency.